Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis
Imtiaz A. Samjoo, Evelyn Worthington, Christopher Drudge, Melody Zhao, Chris Cameron, Dieter A. Häring, Dee Stoneman, Luisa Klotz, Nicholas Adlard
Abstract
Aim: To compare the efficacy of ofatumumab to other disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS). Materials & methods: A network meta-analysis was conducted to determine the relative effect of ofatumumab on annualized relapse rate and confirmed disability progression at 3 months and 6 months. Results: For each outcome, ofatumumab was as effective as other highly efficacious monoclonal antibody DMTs (i.e., alemtuzumab, natalizumab and ocrelizumab). Conclusion: Ofatumumab offers beneficial outcomes for RMS by reducing relapse and disability progression risk.
Topics & Concepts
OfatumumabMedicineNatalizumabOcrelizumabAlemtuzumabMultiple sclerosisInternal medicineMeta-analysisOncologyDiseaseImmunologyRituximabLymphomaTransplantationMultiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersRheumatoid Arthritis Research and Therapies